Mycobacterium tuberculosis, the leading cause of death due to infection, has a dynamic and
immunomodulatory cell envelope. The cell envelope structurally and functionally varies …

Tuberculosis (TB) is a serious global public health challenge that results in significant
morbidity and mortality worldwide. TB is caused by infection with the bacilli Mycobacterium …

There are 9 million cases of active tuberculosis reported annually; however, an estimated
one-third of the world's population is infected with Mycobacterium tuberculosis and remains …

Acinetobacter baumannii, a prominent pathogen responsible for chronic infections in the
blood, urinary tract, and lungs, has a high mortality due to its virulence and limited …

Clinical trials of vaccines against Mycobacterium tuberculosis are well under way and
results are starting to come in. Some of these results are not so encouraging, as exemplified …

In this review we discuss recent progress in the development, testing, and clinical evaluation
of new vaccines against tuberculosis (TB). Over the last 20 years, tremendous progress has …

The granuloma that forms in response to Mycobacterium tuberculosis must be carefully
balanced in terms of immune responses to provide sufficient immune cell activation to inhibit …

Mycobacterium tuberculosis (M. tb), the causative agent of tuberculosis (TB), is the current
leading cause of death due to a single infectious organism. Although curable, the broad …

The past 2 decades have seen a revolution in our approach to therapeutic
immunosuppression. We have moved from relying on broadly active traditional medications …

Bacillus Calmette Guérin (BCG) is the only currently available vaccine against tuberculosis
(TB), but it confers incomplete and variable protection against pulmonary TB in humans and …